NAD plus energy: from blood to a longer walk

Blood NAD+ and physical performance

The word energy has a habit of arriving before the measurement. In NAD+ research, raising blood NAD+ has been more consistent than improving clinical outcomes. That leaves a surprisingly interesting distance to cover between a successful blood test and a useful change in a person's day. I want the walk and the blood sample in the same conversation.

There is something solid underneath the enthusiasm. NAD+ carries electrons in the reactions of cellular metabolism and also supplies enzymes involved in cellular signalling. A coenzyme is a helper molecule an enzyme needs to work. The chemistry gives this subject a reason to exist; it also makes the word energy sound almost irresistibly persuasive.

My initial expectation was a tidy story about replenishment. The human evidence review on NAD+ precursors replaced that expectation with a more particular set of questions: which tissue changed, what function was tested, and how closely the result approached something a person could actually notice. I prefer this messier version. It contains experiments worth arguing about.

NMN and walking distance

The result that gives this site its destination comes from a placebo-controlled NMN trial in healthy middle-aged adults. Over 60 days, blood NAD+ rose, and walking distance and quality-of-life scores improved compared with placebo. NMN is nicotinamide mononucleotide, a compound studied as a precursor to NAD+. Here the investigators went beyond finding more of a molecule in blood: they also asked people to do something.

I give that walking result real weight. Movement is closer to the ordinary meaning of energy than an isolated biochemical value, and a comparison with placebo makes the finding more interesting. The same entry reports no safety issues during the trial. Both observations deserve the boundaries of that experiment: its participants, its intervention and its 60-day duration.

The broader picture remains uneven. The review of human ageing trials describes limited efficacy and sparse information about tissue-specific NAD+ dynamics. My enthusiasm therefore has a fairly precise address: a walking-distance finding in a particular NMN trial. A sweeping claim about renewed vitality would travel far beyond it.

Cellular energy and daily fatigue

Another human experiment makes the distinctions unusually clear. NMN improved muscle insulin sensitivity in prediabetic, postmenopausal women over 10 weeks, while body composition and HbA1c were unchanged. Insulin sensitivity describes how a tissue responds to insulin; HbA1c is a measure the investigators used alongside it. The muscle result is a substantial reason to pay attention, with its own specific population and outcome.

The word energy alone would blur those measurements together. Those measurements deserve separate space, to my mind, so the interesting result retains its actual shape. Walking distance, muscle insulin sensitivity and a rise in blood NAD+ give different answers. None of those measurements by itself supplies a fatigue result. That last step requires a study that actually measures fatigue.

This is where the name NAD Plus Energy earns its place for me. It puts a cellular molecule next to a familiar human hope and leaves room to examine the connection. There is enough here for curiosity without pretending the connection has already been settled.

Explore the measurements

Cellular energy begins with NAD+ carrying electrons, then follows the enzymes that consume it. Blood and muscle moves between sample types, a muscle-biopsy study and a detour through the gut microbiome. Walking and exercise stays with movement: the human walking result, the muscle-metabolism result and a very different experiment in mice. The reading list brings those papers together.